$TNYA News
Last published 1w ago
- 1w agoTNYATenaya Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoTNYATenaya Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireReceived Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. FDA for TN-401 Gene Therapy for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy TN-201 and TN-401 Program Updates on Upcoming
- 1mo agoTNYATenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular CardiomyopathyGlobeNewswireRMAT Designation Supported by Positive Interim Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 which Demonstrated Reduced Arrhythmia Burden Additional Data and Updates on Regulatory Discussions Anticipated in
- 2mo agoTNYATenaya Therapeutics to Participate in Upcoming September Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative
- 3mo agoTNYACG 46TH ANNUAL GROWTH CONFERENCE - TENAYA THERAPEUTICS INCEarnings Call TranscriptsThanks everyone for joining. My name is Whitney Eaton. I'm one of the biomechanical analysts here at the board. It's my pleasure to be joined by Tanaya. I think I said this good afternoon. So Tanaya this afternoon, pleas
- 3mo agoTNYACG 46TH ANNUAL GROWTH CONFERENCE - TENAYA THERAPEUTICS INCEarnings Call TranscriptsThanks everyone for joining. My name is Whitney Eaton. I'm one of the biomechanical analysts here at the board. It's my pleasure to be joined by Tanaya. I think I said this good afternoon. So Tanaya this afternoon, pleas
- 3mo agoTNYATenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswirePositive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Demonstrated Meaningful Improvements in Key Disease Characteristics Additional Data Releases Plus Updates on Regulatory
- 3mo agoTNYATenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative
- 4mo agoTNYATenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireSOUTH SAN FRANCISCO, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative
- 4mo agoTNYATenaya Therapeutics Appoints Eric Hyllengren as Chief Financial OfficerGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative
- 5mo agoTNYATenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in SymptomsGlobeNewswireAll Evaluable Patients Achieved Improvements in Multiple Hallmarks of MYBPC3-Associated HCM Benefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater Symptom Relief and
- 5mo agoTNYATenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative
- 5mo agoTNYATenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative
- 6mo agoTNYAPositive Interim Data from Cohorts 1 and 2 of Tenaya's RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVCGlobeNewswireAll Patients Achieved Meaningful Decreases (Mean = 64%) in Daily Premature Ventricular Contraction Count TN-401 Gene Therapy was Well Tolerated at 3E13 vg/kg and 6E13 vg/kg Doses Post-dose Biopsies Provide Evidence of
- 6mo agoTNYATenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireOne-Year Cohort 1 Data and Initial Cohort 2 Data from RIDGE™-1 Phase 1b/2 Trial of TN-401 for PKP2-Associated ARVC to be Presented at ASGCT 2026 New Data from Both Cohorts of the MyPEAK™-1 Phase 1b/2 Trial
- 6mo agoTNYATenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026GlobeNewswireReadout to Include One-Year Cohort 1 Results and Early Cohort 2 Data; Webcast Conference Call Planned to Review RIDGE-1 Data at ASGCT Additional Presentations at ASGCT Showcase Tenaya's Work with Patients to Advance Gene
- 8mo agoTNYATenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301's Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular DystrophyGlobeNewswireTenaya's Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy New Data Confirm TN-301's Differentiated
- 8mo agoALNYTNYATenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease TherapeuticsGlobeNewswireAgreement Combines Tenaya's Expertise in Identification and Validation ofGenetic Heart Disease Targets with Alnylam's Ability to Deliver Transformational Therapeutics Tenaya to Receive Up to $10 Million in Upfront
- 8mo agoTNYATenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative
- 10mo agoTNYATenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated MilestonesGlobeNewswireAims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK™-1 Trial of Adults with MYBPC3-Associated HCM Expects to Report One-Year
- 11mo agoTNYATenaya Therapeutics Announces Pricing of Public OfferingGlobeNewswireSOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative
- 11mo agoTNYATenaya Therapeutics Announces Proposed Public OfferingGlobeNewswireSOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative
- 11mo agoTNYATenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVCGlobeNewswireTN-401 was Well Tolerated at 3E13 vg/kg dose Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8 Clinically Meaningful Reductions in Arrhythmia Burden Observed in
- 11mo agoTNYATenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene TherapyGlobeNewswireSOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative
- 1y agoTNYATenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswirePresentation of MyPEAK-1 Data and the American Heart Association Scientific Sessions Showed Consistent, Deeper, and Durable Improvement in Measures of Hypertrophy for Cohort 1 Patients Initial TN-201 Cohort 2 Data
- 1y agoTNYATenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic CardiomyopathyGlobeNewswireMyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneous Publication in Cardiovascular Research TN-201 Has Been Generally Well Tolerated at Both Doses Longer-term Follow
- 1y agoTNYATenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025GlobeNewswireOral Presentation on Saturday to Highlight Interim Safety and Efficacy Results from the MyPEAK™-1 Phase 1b/2a Clinical Trial in Adults with MYBPC3-Associated Hypertrophic Cardiomyopathy Second Late-Breaking
- 1y agoTNYATenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative
- 1y agoTNYATenaya Therapeutics to Participate in Upcoming October Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative
- 1y agoTNYATenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative
- 1y agoTNYATenaya Therapeutics, Inc. (TNYA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoTNYATenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative
- 1y agoTNYATenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025GlobeNewswireLargest Noninterventional Natural History Study of People Under 18 with MYBPC3-associated HCM with More than 200 Participants 93% of MyClimb Participants had the Nonobstructive Form of HCM for Which There Are No
- 1y agoTNYATenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative
- 1y agoTNYATenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireEnrollment Complete in Cohorts 1 and 2 of MyPEAK™-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts Cohort 1 of RIDGE™-1 Phase
- 1y agoTNYATenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as DesignedGlobeNewswireEnrollment in Both Dose Cohorts of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Hypertrophic Cardiomyopathy (HCM) Complete; Follow-up Data from Cohort 1 and Initial Data from Cohort 2 Expected in Fourth
- 1y agoTNYATenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswireSOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative
- 1y agoTNYATenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual MeetingGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative
- 1y agoTNYATenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireInterim Data from Low Dose Cohort in MyPEAKTM-1 Clinical Trial of TN-201 Showed Encouraging Safety Profile, Transduction and Expression, Plus Improvements in Hypertrophy and NYHA Classification RIDGE Natural History and
- 1y agoTNYATenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025GlobeNewswireRIDGE is Largest Natural History Study Conducted with More Than 175 Participants Enrolled to Date with Arrhythmogenic Right Ventricular Cardiomyopathy Due to Mutations in the PKP2 Gene Patients Experience High Burden of
- 1y agoTNYATenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual MeetingGlobeNewswireTN-201 Has Been Well Tolerated at 3E13 vg/kg Dose New Biopsy Data Reaffirm Robust Transduction and RNA Expression with TN-201; RNA and Protein Levels Increase Over Time All Cohort 1 Patients with Severe Disease at
- 1y agoTNYATenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy ModelsGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative
- 1y agoTNYATenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific SessionGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative
- 1y agoTNYATenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateGlobeNewswireDosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy MyPEAK-1 Cohort 1 Data Accepted for Late-Breaker Presentation at
- 1y agoTNYATenaya Therapeutics Announces Pricing of Public OfferingGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative
- 1y agoTNYATenaya Therapeutics Announces Proposed Public OfferingGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative
- 1y agoTNYATenaya Therapeutics to Participate in Upcoming March Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative
- 1y agoTNYATenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative MedicineGlobeNewswireFunding will Support Ongoing RIDGE™-1 Clinical Trial of TN-401 Gene Therapy for the Potential Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Initial Data from RIDGE-1 Phase
- 1y agoTNYATenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated MilestonesGlobeNewswireContinued Focus on Driving Advancement of TN-201 and TN-401 Gene Therapies for Cardiomyopathies Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated
- 1y agoTNYATenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic CardiomyopathyGlobeNewswireTN-201 Well Tolerated at 3E13 vg/kg Dose AAV9 Capsid Demonstrated Robust Delivery of TN-201 Transgene to Heart Muscle Cells Resulting in Increasing RNA Expression and an Increase in Protein Levels Observed at One Year